Therapeutic Roles of Antibody Drug Conjugates (ADCs) in Relapsed/Refractory Lymphomas

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Relapsed or refractory lymphoma treatment relies on chemoimmunotherapy and cellular immunotherapy.
• Traditional chemotherapy faces challenges with modest response rates and toxicity, especially in frail patients.
• Antibody drug conjugates (ADCs) are emerging as a promising targeted therapy class.

Purpose of the Study:

• To review clinical data on currently available antibody drug conjugates for lymphoma.
• To discuss the ongoing development and evolving roles of novel antibody drug conjugates.
• To highlight the therapeutic potential and design complexities of ADCs in hematological malignancies.

Main Methods:

• Review of clinical data on existing antibody drug conjugates.
• Analysis of ongoing research and development of novel antibody drug conjugates.
• Discussion of the mechanism of action, targeting, and payload delivery of ADCs.

Main Results:

• Antibody drug conjugates demonstrate significant improvement in therapeutic efficacy for lymphomas.
• ADCs offer better targeting, greater potency, and an improved therapeutic index compared to traditional chemotherapy.
• Several ADCs are actively changing the treatment landscape for lymphomas and other hematological malignancies.

Conclusions:

• Antibody drug conjugates represent a crucial advancement in the treatment of lymphomas.
• ADCs provide a more targeted approach with enhanced efficacy and potentially reduced toxicity.
• The complex design of ADCs, involving antibody, linker, and payload, presents ongoing challenges and opportunities.